FDAnews Device Daily Bulletin
Medical Devices / Inspections and Audits

FDA Finds Eversense CGM Sensor Is Safe for MRIs

Feb. 5, 2019
A A

The FDA determined that patients implanted with the Senseonics’ Eversense implantable continuous glucose monitoring (CGM) system can leave the device in place during MRIs.

The system is comprised of a fluorescence-based sensor, a transmitter worn over the sensor to enable data communication and a mobile app that displays glucose values, alerts and trends. It can be removed, recharged and re-adhered without throwing out the sensor.

The CGM sensor is implanted subcutaneously in a patient’s upper arm by a health care provider during a short in-office procedure.

View today's stories